---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-028604"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:18:54.558337+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech accelerates Phase 3 AML trial recruitment; targets 45 subjects for Q4 2025 unblinding

## Summary
- 13 subjects recruited (10 dosed); target of 20 by end of September 2025.
- Expanding to 8 new active sites in September (Spain, Georgia, Poland, Romania, Italy, Lithuania, US) for total 20.
- On track to recruit 45th subject in Q4 2025 for first unblinding of efficacy and safety data.
- Expects to conclude Part A (75–90 subjects) in first half 2026, then commence Part B (~220 subjects).
- CEO cites operational efficiency and investigator enthusiasm; over 30 active sites expected by year-end.

## SEC filing metadata
- accession: 0001437749-25-028604
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925028604/0001437749-25-028604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925028604/mbrx20250908c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-028604
- JSON: https://secwatch.observer/filing/0001437749-25-028604.json
- Plain text: https://secwatch.observer/filing/0001437749-25-028604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.